The START Center for Cancer Research has administered the first U.S. dose of Moderna's mRNA-4106, a novel pan-tumor antigen therapy candidate, to a patient with advanced solid tumors.
The LAG-3 next-generation immunotherapies market is projected to grow from $463.6 million in 2024 to $5.5 billion by 2035, driven by increasing solid tumor cases and expanding treatment options.
Extended analysis of the RELATIVITY-047 trial shows nivolumab/relatlimab significantly improves overall survival compared to nivolumab alone in advanced melanoma patients.
Researchers identified Aplp1 as a key protein in spreading alpha-synuclein, the protein clumps responsible for Parkinson's disease, between brain cells.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.